Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rupak Dey Sarkar, Samraj Sinha & Nabendu Biswas. (2021) Manipulation of Inflammasome: A Promising Approach Towards Immunotherapy of Lung Cancer. International Reviews of Immunology 40:3, pages 171-182.
Read now
Read now
Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Joao Manuel Santos, Riikka Havunen, Sadia Zafar, Otto Hemminki, Camilla Heiniö, Eleonora Munaro, Mikko Siurala, Suvi Sorsa, Tuomas Mirtti, Petrus Järvinen, Markus Mildh, Harry Nisen, Antti Rannikko, Marjukka Anttila, Anna Kanerva & Akseli Hemminki. (2020) Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. OncoImmunology 9:1.
Read now
Read now
Kiichiro Ninomiya & Katsuyuki Hotta. (2018) Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy 18:10, pages 1015-1021.
Read now
Read now
Roman Groisberg, Hossein Maymani & Vivek Subbiah. (2018) Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. Expert Review of Precision Medicine and Drug Development 3:3, pages 205-213.
Read now
Read now
Mirte Muller, Robert D. Schouten, Cornedine J. De Gooijer & Paul Baas. (2017) Pembrolizumab for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy 17:5, pages 399-409.
Read now
Read now
Articles from other publishers (47)
Ashley Jackson, Nina Chang, Deborah Akurang, Paul Wheatley-Price & Sara Moore. (2023) Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%. JTO Clinical and Research Reports 4:12, pages 100601.
Crossref
Crossref
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan & Wenzhou Zhang. (2022) Current treatments for non-small cell lung cancer. Frontiers in Oncology 12.
Crossref
Crossref
Sheng-Yin To, Li-Ting Kao, Jui-Hu Shih, I-Hsun Li, Tsai-Wang Huang, Chen-Liang Tsai, Chih-Feng Chian, Ching-Liang Ho & Ping-Ying Chang. (2022) Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. International Journal of Environmental Research and Public Health 19:10, pages 5999.
Crossref
Crossref
Gönül Yenilmez Çiftçi, Sümeyra Yoldaş Kılıç, Fatma Yuksel, Gulseren Turhal & Asuman Demiroglu-Zergeroglu. (2022) Novel tetracyclic spermine derivatives of cyclotriphosphazene: Design, synthesis and biological activity. Journal of Molecular Structure 1254, pages 132371.
Crossref
Crossref
Dia Advani, Sudhanshu Sharma, Smita Kumari, Rashmi K. Ambasta & Pravir Kumar. (2022) Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry 22:3, pages 433-468.
Crossref
Crossref
Na Liu, Jinmei Mao, Peizhi Tao, Hao Chi, Wenhui Jia & Chunling Dong. (2022) The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine 101:3, pages e28617.
Crossref
Crossref
L. Federico, D.J. McGrail, S.-E. Bentebibel, C. Haymaker, A. Ravelli, M.-A. Forget, T. Karpinets, P. Jiang, A. Reuben, M.V. Negrao, J. Li, R. Khairullah, J. Zhang, A. Weissferdt, A.A. Vaporciyan, M.B. Antonoff, G. Walsh, S.-Y. Lin, A. Futreal, I. Wistuba, J. Roth, L.A. Byers, P.-O. Gaudreau, N. Uraoka, A.F. Cruz, H. Dejima, R.N. Lazcano, L.M. Solis, E.R. Parra, J.J. Lee, S. Swisher, T. Cascone, J.V. Heymach, J. Zhang, B. Sepesi, D.L. Gibbons & C. Bernatchez. (2022) Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Annals of Oncology 33:1, pages 42-56.
Crossref
Crossref
Lauren E. Wilson, Melissa A. Greiner, Ivy Altomare, Jason Rotter & Michaela A. Dinan. (2021) Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015. Journal of Geriatric Oncology 12:3, pages 375-380.
Crossref
Crossref
David F. McDermott, Jae-Lyun Lee, Georg A. Bjarnason, James M. G. Larkin, Rustem A. Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso-Gordoa, Daniel C. Cho, Poul F. Geertsen, Miguel Angel Climent Duran, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss & Michael B. Atkins. (2021) Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology 39:9, pages 1020-1028.
Crossref
Crossref
Jingjing Qu, Quanhui Mei, Li Liu, Tianli Cheng, Peng Wang, Lijun Chen & Jianying Zhou. (2021) The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592199296.
Crossref
Crossref
Huang-Yu Yang, Chao-Yi Wu, Jia-Jin Chen & Tao-Han Lee. (2020) Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences 21:23, pages 8993.
Crossref
Crossref
Sitanshu S. Singh, Achyut Dahal, Leeza Shrestha & Seetharama D. Jois. (2020) Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. Current Medicinal Chemistry 27:32, pages 5274-5316.
Crossref
Crossref
Yahui Ding, Tianpeng Wang, Tianyang Chen, Chunfeng Xie & Quan Zhang. (2020) Sesquiterpenoids isolated from the flower of Inula japonica as potential antitumor leads for intervention of paclitaxel-resistant non-small-cell lung cancer. Bioorganic Chemistry 101, pages 103973.
Crossref
Crossref
Michael Chahin, Nithya Krishnan, Trevanne Matthews-Hew, Jason Hew & Dat Pham. (2020) Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer. Cureus.
Crossref
Crossref
Zongqiong Sun, Shudong Hu, Yuxi Ge, Jun Wang, Shaofeng Duan, Jiayang Song, Chunhong Hu & Yonggang Li. (2020) Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features. Journal of X-Ray Science and Technology 28:3, pages 449-459.
Crossref
Crossref
Romualdo Barroso-Sousa, Ian E. Krop, Lorenzo Trippa, Zhenying Tan-Wasielewski, Tianyu Li, Wafa Osmani, Chelsea Andrews, Deborah Dillon, Edward T. RichardsonIIIIII, Ricardo G. Pastorello, Eric P. Winer, Elizabeth A. Mittendorf, Jennifer R. Bellon, Jonathan D. Schoenfeld & Sara M. Tolaney. (2020) A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer 20:3, pages 238-245.
Crossref
Crossref
Liang Jiang, Xiaolu Wang, Yuting Wang, Fang Xu, Zhang Zhang, Ke Ding & Xiaoyun Lu. (2020) The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents. RSC Medicinal Chemistry 11:2, pages 293-296.
Crossref
Crossref
Sara Saab, Hussein Zalzale, Zahraa Rahal, Yara Khalifeh, Ansam Sinjab & Humam Kadara. (2020) Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology 11.
Crossref
Crossref
Dan J.M. Nguyen, George Theodoropoulos, Ying-Ying Li, Chunjing Wu, Wei Sha, Lynn G. Feun, Theodore J. Lampidis, Niramol Savaraj & Medhi Wangpaichitr. (2020) Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer. Molecular Cancer Research 18:1, pages 105-117.
Crossref
Crossref
Darragh Halpenny, Elisabeth O’Dwyer, Jeffrey Girshman & Michelle S. Ginsberg. (2020) Imaging of Novel Oncologic Treatments in Lung Cancer Part 1. Journal of Thoracic Imaging 35:1, pages 26-36.
Crossref
Crossref
Keshav Raj Paudel, Nisha Panth, Rudra Pangeni, Rajendra Awasthi, Viney Chawla, Meenu Mehta, Murtaza M. Tambuwala & Philip M. Hansbro. 2020. Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems. Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems
493
516
.
Daye Zhang, Yongxiang Zhang, Zeyuan Cai, Ying Tu & Zhansong Hu. (2019) Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways. Experimental and Therapeutic Medicine.
Crossref
Crossref
Mari Tone, Takehiro Izumo, Nobuyasu Awano, Naoyuki Kuse, Minoru Inomata, Tatsunori Jo, Hanako Yoshimura, Shingo Miyamoto & Hideo Kunitoh. (2019) Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer. Lung Cancer Management 8:2, pages LMT12.
Crossref
Crossref
Zikuan Song, Haoyu Wang & Shuang Zhang. (2019) Negative regulators of Wnt signaling in non-small cell lung cancer: Theoretical basis and therapeutic potency. Biomedicine & Pharmacotherapy 118, pages 109336.
Crossref
Crossref
Marcin Sokołowski, Anna Sokołowska, Grzegorz Mazur & Aleksandra Butrym. (2019) Programmed cell death protein receptor and ligands in haematological malignancies – Current status. Critical Reviews in Oncology/Hematology 135, pages 47-58.
Crossref
Crossref
Corentin Richard, Jean-David Fumet, Sandy Chevrier, Valentin Derangère, Fanny Ledys, Aurélie Lagrange, Laure Favier, Bruno Coudert, Laurent Arnould, Caroline Truntzer, Romain Boidot & François Ghiringhelli. (2019) Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Clinical Cancer Research 25:3, pages 957-966.
Crossref
Crossref
Xingsen Wu, Xiang Li, Zhihong Li, Yancheng Yu, Qidong You & Xiaojin Zhang. (2018) Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry 61:24, pages 11280-11297.
Crossref
Crossref
Hongshu Sui, Ningxia Ma, Ying Wang, Hui Li, Xiaoming Liu, Yanping Su & Jiali Yang. (2018) Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research 2018, pages 1-17.
Crossref
Crossref
Xinpeng Li, Naxin Yuan, Lingdan Lin, Lixia Yin & Yiqing Qu. (2018) Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer. Experimental and Therapeutic Medicine.
Crossref
Crossref
Brett W. Carter. (2018) Immunotherapy in Lung Cancer and the Role of Imaging. Seminars in Ultrasound, CT and MRI 39:3, pages 314-321.
Crossref
Crossref
Xiaohong Zhang & Can Xiao. (2018) Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non‑small cell lung cancer patients. Experimental and Therapeutic Medicine.
Crossref
Crossref
Girish S. Shroff, Patricia M. de Groot, Vassiliki A. Papadimitrakopoulou, Mylene T. Truong & Brett W. Carter. (2018) Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer. Radiologic Clinics of North America 56:3, pages 485-495.
Crossref
Crossref
Neha Kamran, Mahmoud S Alghamri, Felipe J Nunez, Diana Shah, Antonela S Asad, Marianela Candolfi, David Altshuler, Pedro R Lowenstein & Maria G Castro. (2018) Current state and future prospects of immunotherapy for glioma. Immunotherapy 10:4, pages 317-339.
Crossref
Crossref
Bin Zhang, Feng Tao & Hao Zhang. (2018) Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways. Molecular Medicine Reports.
Crossref
Crossref
Ivana Savić & Dejan Oprić. (2018) PD-1/PD-L1: A novel target for immunotherapy in patients with advanced and metastatic non-small cell lung cancer. Medicinski podmladak 69:2, pages 57-64.
Crossref
Crossref
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis & Julie A. Stone. (2017) Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Crossref
Anja Thronicke, Megan L. Steele, Christian Grah, Burkhard Matthes & Friedemann Schad. (2017) Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complementary and Alternative Medicine 17:1.
Crossref
Crossref
Jie Shao, Qiuping Xu, Shu Su, Fanyan Meng, Zhengyun Zou, Fangjun Chen, Juan Du, Xiaoping Qian & Baorui Liu. (2017) Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy. Cellular Immunology 320, pages 38-45.
Crossref
Crossref
Ninglu Yuan, Xiaohe Zhang, Yonghui Cao, Xiaojie Jiang, Si Zhao, Yingying Feng, Yimeng Fan, Zhitao Lu & Hongmei Gao. (2017) Contrast‑enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early‑phase non‑small cell lung cancer. Experimental and Therapeutic Medicine.
Crossref
Crossref
Matthew A. Davidson & Emma J. Shanks. (2017) 3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes. The FEBS Journal 284:17, pages 2705-2731.
Crossref
Crossref
Brett W. Carter, Darragh F. Halpenny, Michelle S. Ginsberg, Vassiliki A. Papadimitrakopoulou & Patricia M. de Groot. (2017) Immunotherapy in Non–Small Cell Lung Cancer Treatment. Journal of Thoracic Imaging 32:5, pages 300-312.
Crossref
Crossref
Daniel J. Boffa, Ryon P. Graf, Michelle C. Salazar, Jessica Hoag, David Lu, Rachel Krupa, Jessica Louw, Lyndsey Dugan, Yipeng Wang, Mark Landers, Mahipal Suraneni, Stephanie B. Greene, Marisa Magaña, Samir Makani, Lyudmila Bazhenova, Ryan V. Dittamore & Jorge Nieva. (2017) Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiology, Biomarkers & Prevention 26:7, pages 1139-1145.
Crossref
Crossref
Karla A. Ruiz-Ceja & Yolanda I. Chirino. (2017) Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomedicine & Pharmacotherapy 90, pages 24-37.
Crossref
Crossref
Woda Shi, Jianxiang Song, Wencai Wang, Yajun Zhang & Shiying Zheng. (2017) MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer. Molecular Medicine Reports 16:5, pages 7329-7336.
Crossref
Crossref
Khalid Abu Ajaj. (2017) A decade of targeted therapy for non-small cell lung cancer. Journal of Pulmonology and Respiratory Research 1:1, pages 023-027.
Crossref
Crossref
Fan Wu, Jie Li, Xin Du, Weisan Zhang, Ping Lei & Qiang Zhang. (2017) Chimeric antibody targeting SRPK-1 in the treatment of non-small cell lung cancer by inhibiting growth, migration and invasion. Molecular Medicine Reports 16:2, pages 2121-2127.
Crossref
Crossref
M. Alper Kursunel & Gunes Esendagli. (2016) The untold story of IFN-γ in cancer biology. Cytokine & Growth Factor Reviews 31, pages 73-81.
Crossref
Crossref